

Niks Professional Ltd.
(Incorporated in the Republic of Singapore)
(Company Registration Number 199804609D)
(the “**Company**”)

**UPDATE ON GROWTH PLAN AND
RE-ALLOCATION OF IPO PROCEEDS**

The Board of Directors (the “**Board**”) of the Company refers to the Company’s offer document dated 18 October 2023 (“**Offer Document**”) in relation to the Company’s initial public offering (the “**IPO**”) and the subsequent updates in the Company’s annual report for the financial year ended 31 December 2023 released on 11 April 2024 and the Company’s SGXNet announcement dated 14 May 2024 (“**14 May Announcement**”). The Company is pleased to provide the following updates on its growth plan and use and re-allocation of IPO proceeds

Update on Growth Plan

The Group opened its fourth medical clinic, Niks Maple North Clinic, in 926 Yishun Central 1 #01-175 Singapore 760926 on 5 August 2024. The new clinic offers greater convenience to patients in the northern part of Singapore as well as those who visit from Malaysia for the Group’s family practice dermatology and aesthetic medical services. The new clinic offers a similar suite of services as the Group’s other clinics and laser and light machines will soon be added.

These machines will be in addition to the ones acquired for clinic and salon use since IPO and during the first half of 2024, details of which have been mentioned in the 14 May Announcement.

In July 2024, the Group placed a deposit for a revolutionary laser system for acne treatment. The system is expected to be launched in Niks Maple Central Clinic at The CentrePoint by the end of this year.

The Group also continues to build up its presence in China’s e-commerce marketplaces and recruit agents for provinces where the Group is currently not represented by any distributor for the sale of its products.

Re-Allocation of IPO Proceeds

The use of IPO proceeds was most recently updated and disclosed in the Company’s Condensed Interim Financial Statements as at and for the first half year ended 30 June 2024 (“**Interim FS**”) which was broadcast via the SGXNet on 9 August 2024.

Further to the above and pursuant to Rule 704(30) of the Listing Manual Section B: Rules of Catalist of the Singapore Exchange Securities Trading Limited, the Board wishes to announce the re-allocation of the use of IPO proceeds as follows:

| Use of IPO proceeds (as set out in the Offer Document) | Amount allocated S\$'000 | Amount used as at 8 August 2024 ** S\$'000 | Amount unused as at 8 August 2024 ** S\$'000 | Re-allocation amount per this announcement S\$'000 | Amount Unused after the re-allocation S\$'000 |
|-------------------------------------------------------------------------------------------------------------------------------|--------------------------------|--------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------------|-----------------------------------------------------------|
| Organic expansion of business through: | 800 | (771) | 29 | 500 | 529 |
| a) Opening of new clinics and outlets, recruitment of healthcare and management professionals, purchase of new equipment; and | | | | | |
| b) Expansion of medical skincare products distribution business in China | | | | | |
| Expansion of business through acquisitions, joint ventures and/or strategic alliances | 2,200 | - | 2,200 | (500) | 1,700 |
| General working capital purposes | 327 | - | 327 | - | 327 |
| Net proceeds | 3,327 | (771) | 2,556 | - | 2,556 |
| Share issue and listing expenses | 1,687 | (1,687) | - | - | - |
| Gross proceeds | 5,014 | (2,458) | 2,556 | - | 2,556 |

** As disclosed in the Interim FS.

The Group continues to be on the lookout for opportunities for the expansion of its business. At this juncture, as there are no firm commitments in relation to such expansion plans, including but not limited to the acquisition of businesses, entry into joint ventures or the formation of strategic alliances, the Board has decided to re-allocate S\$500,000 towards organic expansion. The Board is of the view that the re-allocation is in the best interests of the Company and Shareholders as the re-allocation will enable the Group to effectively deploy its available cash resources.

The Company will make further announcements via SGXNet on the utilisation of the above IPO proceeds as and when such balance of proceeds is materially disbursed and will also provide a status report on the use of proceeds in the next annual report.

BY ORDER OF THE BOARD

Cheng Shoong Tat
Chairman and CEO
9 August 2024

*This announcement has been prepared by the Company and its contents have been reviewed by the Company's Sponsor ("**Sponsor**"), SAC Capital Private Limited. This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Ms Charmian Lim (Telephone: (65) 6232 3210), at 1 Robinson Road, #21-00 AIA Tower, Singapore 048542.*